JP2020506693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506693A5 JP2020506693A5 JP2019540076A JP2019540076A JP2020506693A5 JP 2020506693 A5 JP2020506693 A5 JP 2020506693A5 JP 2019540076 A JP2019540076 A JP 2019540076A JP 2019540076 A JP2019540076 A JP 2019540076A JP 2020506693 A5 JP2020506693 A5 JP 2020506693A5
- Authority
- JP
- Japan
- Prior art keywords
- ace2
- variant
- amino acid
- acid sequence
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims 22
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims 22
- 150000001413 amino acids Chemical group 0.000 claims 9
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 206010019668 Hepatic fibrosis Diseases 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000004531 Renal Artery Obstruction Diseases 0.000 claims 1
- 206010038378 Renal artery stenosis Diseases 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010047295 Ventricular hypertrophy Diseases 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 208000007474 aortic aneurysm Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000024924 glomerular filtration Effects 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 238000007634 remodeling Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023127196A JP2023133564A (ja) | 2017-01-24 | 2023-08-03 | アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762449857P | 2017-01-24 | 2017-01-24 | |
| US62/449,857 | 2017-01-24 | ||
| PCT/US2018/014991 WO2018140456A1 (en) | 2017-01-24 | 2018-01-24 | Active low molecular weight variants of angiotensin converting enzyme 2 (ace2) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127196A Division JP2023133564A (ja) | 2017-01-24 | 2023-08-03 | アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020506693A JP2020506693A (ja) | 2020-03-05 |
| JP2020506693A5 true JP2020506693A5 (enExample) | 2021-03-11 |
| JP7332157B2 JP7332157B2 (ja) | 2023-08-23 |
Family
ID=62979214
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540076A Active JP7332157B2 (ja) | 2017-01-24 | 2018-01-24 | アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 |
| JP2023127196A Pending JP2023133564A (ja) | 2017-01-24 | 2023-08-03 | アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127196A Pending JP2023133564A (ja) | 2017-01-24 | 2023-08-03 | アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US10443049B2 (enExample) |
| EP (1) | EP3574094A4 (enExample) |
| JP (2) | JP7332157B2 (enExample) |
| WO (1) | WO2018140456A1 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7332157B2 (ja) | 2017-01-24 | 2023-08-23 | ノースウェスタン ユニバーシティ | アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 |
| WO2019106085A1 (en) | 2017-11-29 | 2019-06-06 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation |
| JP7340372B2 (ja) * | 2019-07-11 | 2023-09-07 | 浜松ホトニクス株式会社 | 光活性化アデニル酸シクラーゼ |
| US11518788B2 (en) * | 2020-07-10 | 2022-12-06 | Avirus, Inc. | Methods and compositions for treating and preventing viral infection |
| WO2021151043A2 (en) * | 2020-01-23 | 2021-07-29 | Jang Hyun Han | Methods and compositions for treating and preventing viral infection |
| US20210236583A1 (en) * | 2020-02-03 | 2021-08-05 | Yuntao Wu | Targeting the renin-angiotensin system for treatment of environment-and pathogen-induced lung injury |
| TWI886211B (zh) * | 2020-02-13 | 2025-06-11 | 美商西雅圖免疫公司 | 重組ace2-fc融合分子以及製造及使用彼等之方法 |
| EP4073243A4 (en) * | 2020-02-13 | 2024-08-07 | Sichuan Baili Pharmaceutical Co. Ltd. | RECOMBINANT ECA2-FC FUSION MOLECULES, METHODS OF PREPARATION AND USE THEREOF |
| WO2021164723A1 (en) * | 2020-02-20 | 2021-08-26 | Lee Sheau Long | Ginsenoside m1 as a modulator of angiotensin regulating enzymes and its use for treating diseases or conditions including symptoms caused by coronavirus |
| CN111474363A (zh) * | 2020-02-22 | 2020-07-31 | 安徽华培生物科技有限公司 | 一种新型冠状病毒检测方法 |
| WO2021174107A2 (en) * | 2020-02-26 | 2021-09-02 | Northwestern University | Soluble ace2 variants and uses therefor |
| CN115210264A (zh) * | 2020-02-27 | 2022-10-18 | 华辉安健（北京）生物科技有限公司 | 可溶性ace2和融合蛋白，及其应用 |
| WO2021170113A1 (zh) * | 2020-02-29 | 2021-09-02 | 南京金斯瑞生物科技有限公司 | ACE-2-Fc融合蛋白治疗冠状病毒的方法 |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| EP4118109A1 (en) | 2020-03-11 | 2023-01-18 | NantCell, Inc. | Proteinaceous therapeutics |
| US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| JP2023517403A (ja) * | 2020-03-21 | 2023-04-26 | ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニー | Ａｃｅ２および補体経路の二重特異性および三重特異性機能性分子ならびにその使用 |
| WO2021195009A1 (en) * | 2020-03-23 | 2021-09-30 | Sapience Therapeutics, Inc. | Peptide antagonists of ace2-binding proteins |
| CN113444710A (zh) * | 2020-03-25 | 2021-09-28 | 上海英脉德医疗科技有限公司 | ACE2-Fc融合蛋白及其用途 |
| WO2021202456A1 (en) * | 2020-03-30 | 2021-10-07 | The Wistar Institute Of Anatomy And Biology | Synthetic soluble receptor mimics and methods of use for treatment of covid-19 |
| WO2021197501A1 (zh) * | 2020-04-02 | 2021-10-07 | 创观（苏州）生物科技有限公司 | 病毒不易感动物 |
| US20230203466A1 (en) * | 2020-04-03 | 2023-06-29 | Medgenome Inc. | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment |
| JP2023520468A (ja) * | 2020-04-03 | 2023-05-17 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | Ａｃｅ２標的化ウイルスに対して有用な結合タンパク質 |
| EP4138884A1 (en) * | 2020-04-20 | 2023-03-01 | Sorrento Therapeutics, Inc. | Pulmonary administration of ace2 polypeptides |
| WO2021237239A1 (en) * | 2020-05-18 | 2021-11-25 | Northwestern University | Active low molecular weight variant of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye |
| US11773385B2 (en) * | 2020-05-19 | 2023-10-03 | Children's Medical Center Corporation | High-affinity human ACE2 construct for use in diagnosing and treating coronaviruses |
| WO2021247675A1 (en) * | 2020-06-02 | 2021-12-09 | Ngm Biopharmaceuticals, Inc. | Coronavirus-binding agents and uses thereof |
| DE102020207224A1 (de) | 2020-06-09 | 2021-12-09 | Christoph Karle | Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon |
| EP4171603A4 (en) * | 2020-06-25 | 2024-06-26 | Gliknik Inc. | ACE2-FC FUSION PROTEINS AND METHODS OF USE |
| WO2022008642A1 (en) | 2020-07-08 | 2022-01-13 | Apeiron Biologics Ag | Treatment of sars-cov-2 infection with a combination of targets |
| WO2022012688A1 (en) * | 2020-07-17 | 2022-01-20 | Shenzhen Bay Laboratory | Ace2-ig fusion variants |
| KR102492081B1 (ko) * | 2020-07-28 | 2023-01-26 | 재단법인대구경북과학기술원 | 코로나바이러스 감염증 covid-19 치료용 펩타이드 및 이의 용도 |
| US20220041660A1 (en) * | 2020-08-06 | 2022-02-10 | University Of Delaware | Compositions and methods for sequestering viral particles in respiratory tract |
| AU2021322046A1 (en) * | 2020-08-06 | 2023-02-02 | BioNTech SE | Binding agents for coronavirus S protein |
| US20230303654A1 (en) * | 2020-08-11 | 2023-09-28 | City Of Hope | Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells |
| US20230365956A1 (en) * | 2020-10-01 | 2023-11-16 | Systimmune, Inc. | Recombinant ace2-fc fusion molecules and methods of making and using thereof |
| WO2022075667A1 (ko) * | 2020-10-05 | 2022-04-14 | 한양대학교 산학협력단 | 안정화된 ace2 변이체, 이를 이용한 ace2-fc 융합단백질 및 covid-19 예방 또는 치료용 약학 조성물 |
| AU2021362007A1 (en) * | 2020-10-16 | 2023-06-22 | Invisishield Technologies Ltd. | Compositions for preventing or treating viral and other microbial infections |
| US20230406886A1 (en) * | 2020-11-20 | 2023-12-21 | Daegu Gyeongbuk Institute Of Science And Technology | Coronavirus infectious disease covid-19 therapeutic proteins ctp alpha, ctp beta, ctp gamma, ctp delta, and uses thereof |
| WO2022109441A1 (en) | 2020-11-23 | 2022-05-27 | Genentech, Inc. | Methods for modulating host cell surface interactions with sars-cov-2 |
| WO2022119380A1 (ko) * | 2020-12-03 | 2022-06-09 | 주식회사 유틸렉스 | 신규한 ace2 변이체 및 그의 이용 |
| EP4011387A1 (en) * | 2020-12-11 | 2022-06-15 | IMBA-Institut für Molekulare Biotechnologie GmbH | Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2 |
| US20220226489A1 (en) | 2021-01-20 | 2022-07-21 | Singh Biotechnology, Llc | Therapeutics directed against coronavirus |
| CA3206022A1 (en) * | 2021-01-26 | 2022-08-04 | Traian Sulea | Ace2-receptor ectodomain fusion molecules and uses thereof |
| WO2022165246A1 (en) * | 2021-01-29 | 2022-08-04 | The Trustees Of The University Of Pennsylvania | Compositions and method of use of mutant ace2 decoy variants |
| JP7539479B2 (ja) * | 2021-02-10 | 2024-08-23 | シーチュアン バイリ ファーマスーティカル シーオー． エルティーディー． | 組換えａｃｅ２－ｆｃ融合分子、その製造方法及びその使用 |
| WO2022207918A1 (en) | 2021-04-02 | 2022-10-06 | Apeiron Biologics Ag | COVID-19 Therapy |
| WO2022246041A2 (en) * | 2021-05-20 | 2022-11-24 | Achelois Biopharma, Inc. | Compositions and methods for multivalent surface display on enveloped particles |
| CN113324933B (zh) * | 2021-06-01 | 2022-07-26 | 浙江大学 | 一种检测血管紧张素转换酶的方法及其应用 |
| US20240270797A1 (en) * | 2021-06-23 | 2024-08-15 | Cz Biohub Sf, Llc | Coronavirus neutralizing compositions and associated methods |
| US20230181700A1 (en) * | 2021-12-09 | 2023-06-15 | Gliknik Inc. | Ace2 fc fusion proteins and methods of use |
| WO2023201304A2 (en) | 2022-04-14 | 2023-10-19 | Invisishield Technologies Ltd. | Compositions for preventing or treating coronavirus infections |
| EP4508077A1 (en) | 2022-04-14 | 2025-02-19 | Invisishield Technologies Ltd. | Compositions for preventing or treating influenza infections |
| EP4335870A1 (en) | 2022-09-06 | 2024-03-13 | NantCell, Inc. | Peptide therapeutics against sars-cov-2 spike protein |
| CN116023509A (zh) * | 2022-11-18 | 2023-04-28 | 中国药科大学 | 一种融合蛋白及其应用 |
| DE202023100085U1 (de) | 2023-01-09 | 2023-02-03 | Sundararajan Gothandam | Eine doppelte Blockade des Renin-Angiotensin-Systems zur Verringerung der frühen Veränderungen der diabetischen Retinopathie und Nephropathie |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4540930A (en) | 1983-09-12 | 1985-09-10 | Wisconsin Alumni Research Foundation | Plywheel-powered mobile X-ray apparatus |
| US5124154A (en) | 1990-06-12 | 1992-06-23 | Insite Vision Incorporated | Aminosteroids for ophthalmic use |
| US6610497B1 (en) | 1997-12-11 | 2003-08-26 | Millennium Pharmaceuticals, Inc. | Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US20030113726A1 (en) | 2000-12-04 | 2003-06-19 | Zenta Tsuchihashi | Human single nucleotide polymorphisms |
| AT506258A1 (de) | 2007-12-18 | 2009-07-15 | Apeiron Biolog Forschungs Und | Behandlung inflammatorischer krankheiten |
| BR112012007374A2 (pt) * | 2009-09-30 | 2019-09-24 | Glaxo Group Ltd | composição, formulação oral, injetável, inalável ou nebulizável, e, ácido nucleico isolado ou recombinante |
| KR20140140546A (ko) * | 2012-02-10 | 2014-12-09 | 타릭스 파마슈티컬스 엘티디. | 말초 혈관 질환의 치료를 위한 조성물 및 방법 |
| CN104470944B (zh) * | 2012-05-25 | 2021-09-14 | 詹森生物科技公司 | 非天然共有白蛋白结合结构域 |
| KR20150110607A (ko) * | 2013-01-14 | 2015-10-02 | 아페이론 바이오로직스 아게 | 변형된 ａｃｅ２ 폴리펩티드 |
| WO2015058214A1 (en) | 2013-10-18 | 2015-04-23 | Trustees Of The University Of Pennsylvania | Oral delivery of angiotensin converting enzyme 2 (ace2) or angiotensin-(1-7) bioencapsulated in plant cells |
| JP7332157B2 (ja) | 2017-01-24 | 2023-08-23 | ノースウェスタン ユニバーシティ | アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 |
| WO2021174107A2 (en) | 2020-02-26 | 2021-09-02 | Northwestern University | Soluble ace2 variants and uses therefor |
| WO2021237239A1 (en) | 2020-05-18 | 2021-11-25 | Northwestern University | Active low molecular weight variant of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye |
-
2018
- 2018-01-24 JP JP2019540076A patent/JP7332157B2/ja active Active
- 2018-01-24 US US15/878,823 patent/US10443049B2/en active Active
- 2018-01-24 EP EP18745455.8A patent/EP3574094A4/en active Pending
- 2018-01-24 WO PCT/US2018/014991 patent/WO2018140456A1/en not_active Ceased
-
2019
- 2019-10-14 US US16/601,545 patent/US11078471B2/en active Active
-
2021
- 2021-08-02 US US17/391,680 patent/US11891638B2/en active Active
-
2023
- 2023-08-03 JP JP2023127196A patent/JP2023133564A/ja active Pending
-
2024
- 2024-02-02 US US18/431,554 patent/US20240392274A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506693A5 (enExample) | ||
| US20230115655A1 (en) | Engineered polypeptides having enhanced duration of action | |
| JP4175668B2 (ja) | Ｏｂ融合タンパク質組成物および方法 | |
| TWI853223B (zh) | Gdf15融合蛋白及其用途 | |
| US7112659B2 (en) | OB fusion protein compositions and methods | |
| US8420098B2 (en) | Fibronectin based scaffold domain proteins that bind to PCSK9 | |
| JP2018070625A5 (enExample) | ||
| JP2016511752A5 (enExample) | ||
| US20180305430A1 (en) | Engineered Polypeptides Having Enhanced Duration of Action and Reduced Immunogenicity | |
| JP2019085420A (ja) | エラスチン様ペプチドを含む治療剤 | |
| JP5907970B2 (ja) | インターロイキン−２２のウイルス性肝炎の治療における応用 | |
| JP2017531613A5 (enExample) | ||
| JP6825181B2 (ja) | 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用 | |
| JP2008521426A5 (enExample) | ||
| JP2022547051A (ja) | 治療用融合タンパク質 | |
| US20250295737A1 (en) | Treatment Using Heterodimeric Relaxin Fusions | |
| US20180228872A1 (en) | Methods and compositions related to long half-life coagulation complexes | |
| KR102508649B1 (ko) | 사멸 수용체 작용제로 전신성 경화증 완화 | |
| RU2021136703A (ru) | Новый модифицированный слитый белок fc-фрагмента иммуноглобулина и его применение |